11-Feb-2025 3:05 PM CST - Business Wire Sage Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Highlights Pipeline and Business Updates Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2024. We are proud to have helped thousands of women with postpartum depression in 2024. ZURZUVAE is being recognized as an important treatment option for women with postpartum depression and we believe it will continue to be instrumental in accelerating progress in maternal mental health, said Barry Greene,
28-Jan-2025 3:30 PM CST - Business Wire Sage Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025 Sage Therapeutics, Inc. (NASDAQ: SAGE), today announced that it will host a live webcast on Tuesday, February 11, 2025 at 4:30 p.m. ET to review fourth quarter and full year 2024 financial results and discuss recent business updates. The webcast can be accessed on the Investor page of Sages website at investor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. About Sage Therapeu
12-Jan-2025 5:00 PM CST - Business Wire Sage Therapeutics to Present 2025 Strategic Focus at 43rd Annual J.P. Morgan Healthcare Conference Sage Therapeutics, Inc. (Nasdaq: SAGE) today announced that Chief Executive Officer Barry Greene will discuss the Companys strategic focus areas for 2025 at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California. As part of this presentation, Mr. Greene will discuss the ongoing commercialization and strategic growth plans for ZURZUVAE (zuranolone), the first and only once-daily 14-day oral treatment for adults with postpartum depressi
8-Jan-2025 5:30 AM CST - Business Wire Sage Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 Sage Therapeutics, Inc. (NASDAQ: SAGE) today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 8:15 a.m. PT in San Francisco, CA. A live webcast of the presentation can be accessed on the Investor page of Sages website at investor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. About Sage Therapeutic
26-Nov-2024 6:00 AM CST - Business Wire Sage Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference Sage Therapeutics, Inc. (NASDAQ: SAGE), today announced that the Company will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024, at 9:00 a.m. ET in New York, NY. A live webcast of the presentation can be accessed on the Investor page of Sages website at investor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. A
29-Oct-2024 3:05 PM CST - Business Wire Sage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the third quarter ended September 30, 2024. We are committed to harnessing the full potential of ZURZUVAE as a transformative treatment for women with postpartum depression. Our encouraging third quarter results, highlighted by continued growth in revenue and shipments, brings us one step closer to our goal of establishing ZURZUVAE as the standard of care to h
15-Oct-2024 5:30 AM CST - Business Wire Sage Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024 Sage Therapeutics, Inc. (NASDAQ: SAGE), today announced that it will host a live webcast on Tuesday, October 29, 2024 at 4:30 p.m. ET to review third quarter 2024 financial results and discuss recent business updates. The webcast can be accessed on the Investor page of Sages website at investor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. About Sage Therapeutics Sage Therap
11-Feb-2025 3:05 PM CST - Business Wire Sage Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Highlights Pipeline and Business Updates Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2024. We are proud to have helped thousands of women with postpartum depression in 2024. ZURZUVAE is being recognized as an important treatment option for women with postpartum depression and we believe it will continue to be instrumental in accelerating progress in maternal mental health, said Barry Greene,
28-Jan-2025 3:30 PM CST - Business Wire Sage Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025 Sage Therapeutics, Inc. (NASDAQ: SAGE), today announced that it will host a live webcast on Tuesday, February 11, 2025 at 4:30 p.m. ET to review fourth quarter and full year 2024 financial results and discuss recent business updates. The webcast can be accessed on the Investor page of Sages website at investor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. About Sage Therapeu
12-Jan-2025 5:00 PM CST - Business Wire Sage Therapeutics to Present 2025 Strategic Focus at 43rd Annual J.P. Morgan Healthcare Conference Sage Therapeutics, Inc. (Nasdaq: SAGE) today announced that Chief Executive Officer Barry Greene will discuss the Companys strategic focus areas for 2025 at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California. As part of this presentation, Mr. Greene will discuss the ongoing commercialization and strategic growth plans for ZURZUVAE (zuranolone), the first and only once-daily 14-day oral treatment for adults with postpartum depressi
8-Jan-2025 5:30 AM CST - Business Wire Sage Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 Sage Therapeutics, Inc. (NASDAQ: SAGE) today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 8:15 a.m. PT in San Francisco, CA. A live webcast of the presentation can be accessed on the Investor page of Sages website at investor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. About Sage Therapeutic
26-Nov-2024 6:00 AM CST - Business Wire Sage Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference Sage Therapeutics, Inc. (NASDAQ: SAGE), today announced that the Company will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024, at 9:00 a.m. ET in New York, NY. A live webcast of the presentation can be accessed on the Investor page of Sages website at investor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. A
29-Oct-2024 3:05 PM CST - Business Wire Sage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the third quarter ended September 30, 2024. We are committed to harnessing the full potential of ZURZUVAE as a transformative treatment for women with postpartum depression. Our encouraging third quarter results, highlighted by continued growth in revenue and shipments, brings us one step closer to our goal of establishing ZURZUVAE as the standard of care to h
15-Oct-2024 5:30 AM CST - Business Wire Sage Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024 Sage Therapeutics, Inc. (NASDAQ: SAGE), today announced that it will host a live webcast on Tuesday, October 29, 2024 at 4:30 p.m. ET to review third quarter 2024 financial results and discuss recent business updates. The webcast can be accessed on the Investor page of Sages website at investor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. About Sage Therapeutics Sage Therap
